3,881
edits
Changes
HAEM5:Volunteer Assignments and Opportunities (view source)
Revision as of 12:55, 20 December 2023
, 12:55, 20 December 2023no edit summary
|
|
|
|
|
|B-Lymphoblastic Leukemia/Lymphoma, Not Otherwise Specified
|
|Holli Drendel
|
|PENDING
|
|
|
|
|
|
|
|
|
|B-Lymphoblastic Leukemia/Lymphoma with Hyperdiploidy
|Afia Hasnain, MBBS, PhD; Yassmine Akkari, PhD, FACMG
|Afia Hasnain, MBBS, PhD; Yassmine Akkari, PhD, FACMG
|
|PENDING
|
|
|
|
|
|
|
|
|
|B-Lymphoblastic Leukemia/Lymphoma with Hypodiploidy
|Ashwini Yenamandra PhD FACMG Lisa Smith PhD FACMG Yassmine Akkari PhD FACMG
|Ashwini Yenamandra PhD FACMG Lisa Smith PhD FACMG Yassmine Akkari PhD FACMG
|
|Complete
|
|
|
|
|B-lymphoblastic leukaemia/lymphoma with iAMP21
|B-lymphoblastic leukaemia/lymphoma with iAMP21
|Disease
|Disease
|
|Holli authoring - Complete? Looks like needs more editing of tables
|
|
|
|
|
|
|
|
|
|B-Lymphoblastic Leukemia/Lymphoma with iAMP21 [but was completed as a 5th edition page by Holli]
|Holli M. Drendel, PhD, FACMGG, Carolinas Pathology Group, Charlotte
|Holli M. Drendel, PhD, FACMGG, Carolinas Pathology Group, Charlotte
|
|?Complete
|
|
|
|
|
|
|
|
|
|B-Lymphoblastic Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1
|Afia Hasnain, MBBS, PhD; Yassmine Akkari, PhD, FACMG
|Afia Hasnain, MBBS, PhD; Yassmine Akkari, PhD, FACMG
|
|PENDING
|
|
|
|
|
|
|
|
|
|B-Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like
|Mark G. Evans, MD, University of California, Irvine Fabiola Quintero-Rivera, MD, University of California, Irvine
|Mark G. Evans, MD, University of California, Irvine Fabiola Quintero-Rivera, MD, University of California, Irvine
|
|Complete
|
|
|
|
|
|
|
|
|
|B-Lymphoblastic Leukemia/Lymphoma with t(v;11q23.3); KMT2A-Rearranged
|Yassmine Akkari Nicolas Millan
|Yassmine Akkari Nicolas Millan
|
|PENDING
|
|
|
|
|
|
|
|
|
|B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion
|Marilena Melas, PhD; Yassmine Akkari, PhD, FACMG Cancer Category/Type B-Lymphoblastic Leukemia/Lymphoma
|Marilena Melas, PhD; Yassmine Akkari, PhD, FACMG Cancer Category/Type B-Lymphoblastic Leukemia/Lymphoma
|
|PENDING
|
|
|
|
|
|
|
|
|
|NEW (No Prior)
|
|NEW (No Prior)
|
|NEW (No Prior)
|
|NEW (No Prior)
|
|NEW (No Prior)
|-
|-
|B lymphoblastic leukaemia/lymphoma with TCF3::PBX1 fusion
|B lymphoblastic leukaemia/lymphoma with TCF3::PBX1 fusion
|
|
|
|
|
|B-Lymphoblastic Leukemia/Lymphoma with t(1;19)(q23;p13.3); TCF3-PBX1
|Binu Porath, PhD. Vanderbilt University Medical Center, Nashville, TN Linda D. Cooley, MD, MBA. Children's Mercy Kansas City, Kansas City, MO
|Binu Porath, PhD. Vanderbilt University Medical Center, Nashville, TN Linda D. Cooley, MD, MBA. Children's Mercy Kansas City, Kansas City, MO
|
|PENDING
|
|
|
|
|
|
|
|
|
|B-Lymphoblastic Leukemia/Lymphoma with t(5;14)(q31.1;q32.1); IGH/IL3
|Binu Porath, PhD. Vanderbilt University Medical Center, Nashville, TN Linda D. Cooley, MD, MBA. Children's Mercy Kansas City, Kansas City, MO
|Binu Porath, PhD. Vanderbilt University Medical Center, Nashville, TN Linda D. Cooley, MD, MBA. Children's Mercy Kansas City, Kansas City, MO
|
|PENDING
|
|
|
|
|
|
|
|
|
|NEW (No Prior)
|
|NEW (No Prior)
|
|NEW (No Prior)
|
|NEW (No Prior)
|
|NEW (No Prior)
|-
|-
|B-lymphoblastic leukaemia/lymphoma with other defined genetic alterations
|B-lymphoblastic leukaemia/lymphoma with other defined genetic alterations
|
|
|
|
|
|NEW (No Prior)
|
|NEW (No Prior)
|
|NEW (No Prior)
|
|NEW (No Prior)
|
|NEW (No Prior)
|-
|-
|B-lymphoblastic leukaemia/lymphoma, NOS
|B-lymphoblastic leukaemia/lymphoma, NOS
|
|
|
|
|
|NEW (No Prior)
|
|NEW (No Prior)
|
|NEW (No Prior)
|
|NEW (No Prior)
|
|NEW (No Prior)
|-
|-
|RESOLVE 4th edition ALL-Related NON-WHO entities content
|RESOLVE 4th edition ALL-Related NON-WHO entities content